A recent study published in Frontiers in Pediatrics reports preliminary but promising findings on an experimental fecal microbiota transplantation (FMT) approach for children with autism spectrum disorder (ASD), a heterogeneous neurodevelopmental disorder characterized by impairments in social communication, restricted behaviors, and sensory dysregulation. Despite advances in behavioral therapies, ASD continues to lack consistently effective, scalable biological treatments, prompting growing interest in alternative mechanistic pathways such as the gut–brain axis.
The study builds on accumulating evidence linking alterations in the intestinal microbiome to neurobehavioral outcomes via bidirectional signaling pathways encompassed within the gut-brain axis. Dysbiosis has been implicated in modulating immune responses, neurotransmitter production, and metabolic signaling, all of which may contribute to ASD pathophysiology. The investigators evaluated a novel FMT formulation, SHIN-1, developed using hydrogen nanobubble water, designed to simplify conventional transplantation protocols.
Unlike traditional FMT approaches that typically require antibiotic pretreatment and bowel lavage with polyethylene glycol, the SHIN-1 protocol omits these preparatory steps, potentially reducing procedural burden and improving tolerability. In this prospective, single-arm study, 30 pediatric patients with ASD (male-to-female ratio ~3:1) received rectal administration of the formulation via catheter or enema. Clinical outcomes were assessed using validated instruments, including the Social Responsiveness Scale (SRS-2) to quantify core ASD symptomatology, alongside measures of sensory processing, gastrointestinal function, and psychological parameters such as anxiety and depressive features. The intervention was associated with improvements across multiple domains, including reductions in core symptom severity, enhanced sensory regulation, amelioration of gastrointestinal disturbances, and modest improvements in mood-related measures. The treatment was well tolerated, with no significant adverse events reported over the study period.
These findings suggest that microbiome-targeted interventions may exert broader therapeutic effects than conventional behavioral strategies by addressing both neurobehavioral and physiological dimensions of ASD. The simplified administration protocol further highlights potential advantages in terms of feasibility and patient compliance. While preliminary, the observed consistency of improvements across standardized clinical measures provides a compelling rationale for further investigation. Larger, randomized, double-blind, placebo-controlled trials will be essential to validate efficacy, establish long-term safety, and determine the clinical applicability of SHIN-1 and similar microbiome-based interventions. If substantiated, such approaches may represent a significant advancement in the therapeutic landscape of ASD, offering a more integrated strategy targeting both central and peripheral contributors to disease expression.
Reference
- Shirotani M, Shimizu S, Kitamura K, Mikawa Y, Haruna R, Kawai Y, et al. Safety and efficacy of a novel fecal microbiota transplantation method using hydrogen nanobubble water without antibiotics or bowel cleansing in children with autism spectrum disorder: an open-label, single-arm study demonstrating improvements in core and comorbidity symptoms. Front Pediatr. 2026 Mar 11;14.